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BACKGROUND: Endometrial cancer is strongly associated with body mass index (BMI), but the influence of BMI history and of different
types of obesity is uncertain.
METHODS: A case–control study was carried out in Italy including 454 cases and 908 controls admitted to hospital for acute
non-hormone-related conditions. Odds ratios (ORs) and 95% confidence intervals (CIs) were computed using multivariate logistic
and spline regression models.
RESULTS: The OR for BMI 430 at diagnosis compared with 20 to o25kgm
 2 was 4.08 (95% CI: 2.90–5.74). The association for BMI
was monotonic with a possible steeper increase for BMI above 28. Conversely, waist-to-hip ratio (WHR) showed a bell shaped curve
with increased OR (2.10; 95% CI: 1.43–3.09) in the intermediate tertile only. After stratification by BMI at diagnosis, history of weight
loss and BMI at age 30 did not influence endometrial cancer risk. History of obesity in middle age had a weak and not significant
adverse effect among obese women (OR¼1.60; 95% CI: 0.52–4.96).
CONCLUSION: The predominant importance of recent weight compared to lifetime history, justifies encouraging weight reduction in
women at any age.
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Endometrial cancer is strongly associated with overweight and
obesity (Levi et al, 1992; La Vecchia et al, 1997; Calle et al, 2003),
which account for 30% (B16000 new cases per year) of cases among
European women (Renehan et al, 2010). This association reflects the
relationship between adiposity and high levels of unopposed
oestrogens, which derive from increased frequency of anovulatory
cycles (in pre-menopausal women) or the enhanced conversion of
adrenal androgens into oestrogens in adipose tissue (in post-
menopausal women; Key and Pike, 1988; Parazzini et al,1 9 9 1 ) .T h e
excess risk for endometrial cancer increases with age, reflecting the
increasing importance of androgen conversion as ovarian activity
has ceased (Key and Pike, 1988; Parazzini et al,1 9 9 1 ) .
Some studies have suggested that, among women of normal
body mass index (BMI) at diagnosis, there is little additional excess
risk of endometrial cancer in relation to history of overweight
(Le Marchand et al, 1991; Levi et al, 1992; Shu et al, 1992;
Swanson et al, 1993; Olson et al, 1995; Terry et al, 1999;
Weiderpass et al, 2000; Schouten et al, 2004; Xu et al, 2005;
Trentham-Dietz et al, 2006; Chang et al, 2007; Friedenreich et al,
2007; WCRF/AICR – World Cancer Research Fund/American
Institute for Cancer Research, 2007; Park et al, 2010). However,
data on the relationship between lifetime changes in BMI and
endometrial cancer risk are limited and difficult to assess because
a monotonic pattern (gradual weight increases during life)
predominates in most studied populations (Le Marchand et al,
1991; Levi et al, 1992; Swanson et al, 1993; Olson et al, 1995;
Xu et al, 2005, 2006; Park et al, 2010). Similarly, there is limited
information on the influence on endometrial cancer risk of
different types of obesity, in particular, waist-to-hip ratio (WHR)
(WCRF/AICR – World Cancer Research Fund/American Institute
for Cancer Research, 2007). In some studies from Europe
(Friedenreich et al, 2007), North America (Austin et al, 1991;
Schapira et al, 1991; Swanson et al, 1993; Goodman et al, 1997),
and China (Shu et al, 1992; Xu et al, 2005), BMI and waist
circumference were stronger predictors of endometrial cancer
risk than WHR, but the issue remains open to discussion.
To further explore these issues, we used data on BMI at different
ages and measures of waist and hip at diagnosis from a
case–control study on endometrial cancer carried out in different
parts of Italy (Zucchetto et al, 2009).
MATERIALS AND METHODS
A case–control study on endometrial cancer was conducted
between 1992 and 2006 in three Italian areas: Pordenone and Milan
in the north and Naples in the south (Lucenteforte et al, 2008;
Received 5 October 2010; revised 11 January 2011; accepted 3 February
2011; published online 8 March 2011
*Correspondence: Dr L Dal Maso, E-mail: epidemiology@cro.it
British Journal of Cancer (2011) 104, 1207–1213
& 2011 Cancer Research UK All rights reserved 0007– 0920/11
www.bjcancer.com
E
p
i
d
e
m
i
o
l
o
g
yZucchetto et al, 2009). Cases were 454 women (median age 60
years, range 18–79 years) with histologically confirmed endome-
trial cancer and no previous history of cancer; those diagnosed less
than 1 year before recruitment were eligible. Controls were 908
women (median age 61 years, range 19–79 years) admitted to the
same network of hospitals of cases for a wide spectrum of non-
neoplastic, acute illnesses. Women with a history of hysterectomy
or admitted for gynaecological or hormone-related conditions
were not eligible as controls. The reasons for hospital admission
among controls were trauma (36%), orthopaedic diseases (32%),
acute surgical conditions (9%), and other illnesses (eye, nose, ear,
skin, or dental disorders, 23%). Cases and controls were frequency
matched on study centre and 5-year age, with a 1:2 ratio.
Centrally trained staff interviewed eligible women during their
hospital stay. Less than 5% of the approached cases and controls
refused the interview. The response rates were similar across
hospitals and geographic areas. All interviews were conducted
using a structured questionnaire, which included information on
age, education and other socioeconomic factors, physical activity,
smoking habit, alcohol intake, a validated food frequency
questionnaire, a problem-oriented medical history, and history
of cancer in first degree relatives. In a detailed section of the
questionnaire, women were asked to report their height and weight
at 1 year before cancer diagnosis or interview (for controls; referred
to, for brevity, as measures at diagnosis), weight at age 30 and 50
years, lifelong highest and lowest weight, and perceived body size at
age 12 years (i.e., thinner than, same as, heavier than peers). BMI was
computed as weight divided by squared height (kgm
 2). The
interviewers measured the circumference of the waist (2cm above
the umbilicus) and hip (maximal protrusion) at the time of interview
and computed WHR. Waist-to-height ratio (WHtR) was also
computed. Waist or hip could not be measured in 89% of women
interviewed in Milan centre, leading to a lack of information for
WHR and WHtR in 33% of cases and 35% of controls. However, in
the overall study, median BMI in women with a measured WHR was
not substantially different from that in women for whom the
information on WHR or WHtR was missing (26.4 and 26.2,
respectively, among cases and 26.1 and 25.8 among controls).
Table 1 Distribution of 454 endometrial cancer cases and 908 controls
according to selected variables, Italy, 1992–2006
Cases Controls
No. % No. %
Age (years)
o50 67 14.8 134 14.8
50–59 140 30.8 280 30.8
60–69 166 36.6 332 36.6
X70 81 17.8 162 17.8
Study center
Aviano–Pordenone 237 52.2 474 52.2
Milan 140 30.8 280 30.8
Naples 77 17.0 154 17.0
Education (years)
o7 263 57.9 553 60.9
7–11 119 26.2 225 24.8
X12 72 15.9 130 14.3
Smoking status
Never 331 72.9 647 71.3
Current 75 16.5 157 17.3
Former 48 10.6 104 11.5
Age at menarche (years)
a
o11 24 5.3 44 4.9
11–13 283 62.6 475 52.7
14–16 137 30.3 345 38.3
X17 8 1.8 38 4.2
Parity
Nulliparous 68 15.0 126 13.9
Parous 386 85.0 782 86.1
Oral contraceptive use
Never 408 89.9 790 87.0
Ever 46 10.1 118 13.0
Hormone replacement therapy
Never 405 89.2 830 91.4
Ever 49 10.8 78 8.6
Menopausal status
a
Pre/peri 85 19.2 174 19.3
Post 358 80.8 726 80.7
aThe sum does not add up to the total because of some missing values.
Table 2 Distribution of 454 endometrial cancer cases and 908 controls,
and corresponding odds ratio (OR) with 95% confidence intervals (CIs)
a,
according to body mass index (BMI) at diagnosis and at different ages,
b Italy,
1992–2006
Cases Controls
No. (%) No. (%) OR (95% CI)
Height (cm)
o160 152 (33.5) 258 (28.5) 1
c
160–164 148 (32.6) 280 (31.0) 0.90 (0.66–1.21)
X165 154 (33.9) 366 (40.5) 0.71 (0.53–0.95)
w
2 for trend (P-value) 5.39 (P¼0.02)
Weight (kg)
o64 109 (24.0) 355 (39.1) 1
c
64–74 145 (31.9) 311 (34.3) 1.51 (1.10–2.06)
X75 200 (44.1) 242 (26.7) 2.71 (1.99–3.70)
w
2 for trend (P-value) 40.17 (Po0.01)
Body mass index (kgm
 2)
o20 11 (2.4) 58 (6.4) 0.56 (0.27–1.15)
20 to o25 115 (25.3) 355 (39.3) 1
c
25 to o30 160 (35.2) 351 (38.8) 1.41 (1.05–1.90)
X30 168 (37.0) 140 (15.5) 4.08 (2.90–5.74)
w
2 for trend (P-value) 67.95 (Po0.01)
BMI (kgm
 2) 5-Unit increase 1.89 (1.65–2.17)
Perceived body size at age 12 years
Thinner than peers 146 (32.3) 351 (39.1) 1
c
Same than peers 173 (38.3) 341 (38.0) 1.12 (0.85–1. 94)
Heavier than peers 133 (29.4) 206 (22.9) 1.45 (1.06–1.98)
w
2 trend (P-value) 5.19 (P¼0.02)
BMI at age 30 years
d (kgm
 2)
o20 55 (12.6) 179 (21.9) 0.57 (0.40–0.83)
20 to o25 252 (57.8) 473 (57.8) 1
c
25 to o30 100 (22.9) 134 (16.4) 1.40 (1.02–1.95)
X30 29 (6.7) 33 (4.0) 1.78 (1.01–3.14)
w
2 for trend (P-value) 18.95 (Po0.01)
BMI at age 50 years
e (kgm
 2)
o20 7 (1.9) 54 (7.7) 0.39 (0.17–0.91)
20 to o25 138 (37.3) 339 (48.3) 1
c
25 to o30 129 (34.9) 223 (31.9) 1.48 (1.08–2.04)
X30 96 (26.0) 84 (12.0) 3.37 (2.26–5.04)
w
2 for trend (P-value) 42.33 (Po0.01)
aORs from conditional logistic regression models, conditioned on age and study
centre, adjusted for year of interview, education, smoking status, age at menarche, age
at menopause, oral contraceptive use, parity, and hormone replacement therapy use.
bThe sum does not add up to the total because of some missing values.
cReference
category.
dWomen X30 years old only.
eWomen X50 years old only.
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X30kgm
 2) were used to facilitate comparisons with previous
studies. Tertiles obtained from the combined distribution of cases
and controls were used to assess other anthropometric measures.
A conditional logistic regression model was used to compute odds
ratios (ORs) and the corresponding 95% confidence intervals
(CIs). All analyses were conditioned on age and study centre and
adjusted for calendar period of interview, years of education,
smoking habits, age at menarche and at menopause, parity, and
use of oral contraceptives and hormone replacement therapy.
Additional adjustment for alcohol intake, and occupational and
recreational physical activity did not materially modify the risk
estimates. To avoid potentially arbitrary categorisations, the
‘dose–risk’ relationship between BMI at diagnosis or WHR and
endometrial cancer risk was assessed using logistic cubic
regression splines (Greenland, 1995; Rosenberg et al, 2003;
Dal Maso et al, 2007), and appropriate point-wise CIs were
computed. The optimal number of segments of BMI or WHR was
selected in order to minimise the Akaike information criterion
(Akaike, 1973).
RESULTS
Table 1 shows the distribution of 454 endometrial cancer cases and
908 controls according to matching variables (age and study
centre) and potential confounders. By design, cases and controls
had equal distribution of age and study centre. No association was
found with education or smoking status. Endometrial cancer risk
was inversely associated with age at menarche, parity, and oral
contraceptive use, whereas directly associated with age at
menopause (Zucchetto et al 2009).
The distribution of endometrial cancer cases and controls, and
the corresponding ORs, according to height, weight, BMI at
diagnosis and at different ages are shown in Table 2. An inverse
association with height was observed (OR¼0.71; 95% CI:
0.53–0.95; for women X165cm tall compared with o160cm).
Weight and BMI were directly related to endometrial cancer risk;
compared with normal weight women (BMI 20 to o25kgm
 2), the
ORs were 0.56 (95% CI: 0.27–1.15) in women with BMI o20, 1.41
(95% CI: 1.05–1.90) and 4.08 (95% CI: 2.90–5.74) in women with
BMI 25 to o30 and BMI X30, respectively. OR was 1.45
(95% CI: 1.06–1.98) among women who reported to have been
heavier than their peer group at age 12 years. Compared with
BMI 20 to o25, the OR for BMI X30 at age 30 was 1.78 (95% CI:
1.01–3.14), and 3.37 (95% CI: 2.26–5.04) for BMIX30 at age 50
(Table 2). Decreases from highest BMI by X2kgm
 2 were weakly
associated with reductions in endometrial cancer risk (OR vs no
decrease in BMI during lifetime¼0.80; 95% CI: 0.59–1.08), but
the association disappeared by adjustment for BMI at diagnosis
Table 3 Distribution of 454 endometrial cancer cases and 908 controls,
and corresponding odds ratio (OR) with 95% confidence intervals (CIs),
a
according to measures of fat distribution,
b Italy, 1992–2006
Cases Controls
No. (%) No. No. OR (95% CI)
Waist circumference (cm)
o84 79 (25.7) 221 (37.2) 1
c
84–95 101 (32.9) 226 (38.1) 1.22 (0.83–1.79)
X96 127 (41.4) 147 (24.8) 2.68 (1. 78–4.03)
w
2 for trend (P-value) 22.51 (Po0.01)
Hip circumference (cm)
o100 87 (28.4) 218 (36.8) 1
c
100 to108 96 (31.4) 204 (34.5) 1.35 (0.92–1.98)
X109 123 (40.2) 170 (28.7) 2.49 (1.66–3.72)
w
2 for trend (P-value) 18.99 (Po0.01)
Waist-to-hip ratio
o0.833 71 (23.3) 224 (37.8) 1
c
0.833 to o0.890 129 (42.2) 177 (29.9) 2.10 (1.43–3.09)
X0.890 106 (34.6) 191 (32.3) 1.33 (0.89–1.97)
w
2 for trend (P-value) 1.38 (P¼0.24)
Waist-to-height ratio
o0.52 77 (25.1) 237 (40.0) 1
c
0.52 to o0.59 101 (32.9) 200 (33.8) 1.66 (1.12–2.46)
X0.59 129 (42.0) 155 (26.1) 3.10 (2.03–4.73)
w
2 for trend (P-value) 27.53 (Po0.01)
aORs from conditional logistic regression models, conditioned on age and study
centre, adjusted for year of interview, education, smoking status, age at menarche,
age at menopause, oral contraceptives use, parity, and hormone replacement therapy
use.
bThe sum does not add up to the total because of some missing values.
cReference category.
Table 4 Odds ratio (OR) with 95% confidence intervals (CIs)
a of 454 endometrial cancer cases (CA) and 908 controls (CO), according to height, waist-
to-hip ratio, and waist-to-height ratio in strata of recent body mass index at diagnosis, Italy, 1992–2006
Body mass index (kgm
 2) at diagnosis
o25 25 to o30 X30
CA:CO OR (95% CI) CA:CO OR (95% CI) CA:CO OR (95% CI)
Height (cm)
o160 29:103 1
b 52:102 1
b 71:53 1
b
160–164 42:126 1.25 (0.69–2.25) 53:110 0.93 (0.56–1.54) 53:44 0.97 (0.53–1.79)
X165 55:184 1.13 (0.65–1.96) 55:139 0.74 (0.44–1.23) 44:43 0.69 (0.37–1.30)
Waist-to-hip ratio
o0.833 33:135 1
b 22:70 1
b 16:19 1
b
0.833 to o0.890 29:71 1.70 (0.87–3.34) 50:78 1.74 (0.88–3.45) 50:28 2.95 (1.04–8.39)
X0.890 17:60 1.01 (0.49–2.09) 38:88 1.11 (0.55–2.25) 51:43 1.17 (0.43–3.15)
Waist-to-height ratio
o0.52 55:195 1
b 22:41 1
b 0:1 0 (—)
0.52 to o0.59 21:64 1.68 (0.84–3.36) 59:122 0.92 (0.45–1.87) 21:14 1
b
X0.59 4:6 4.69 (0.97–22.76) 29:74 0.82 (0.35–1.90) 96:75 0.80 (0.31–2.05)
aORs from conditional logistic regression models, conditioned on age and study centre, adjusted for year of interview, education, smoking status, age at menarche, age at
menopause, oral contraceptives use, parity, and hormone replacement therapy use.
bReference category.
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0.70–1.32; data not shown).
Table 3 shows the relationship between waist and hip
circumferences, WHR, and WHtR and endometrial cancer risk.
Significant trends of risk emerged, with the increase of waist
circumference (OR for X96 vs o84cm: 2.68; 95% CI: 1.78–4.03),
hip circumference (OR for X109 vs o100cm¼2.49; 95%
CI: 1.66–3.72), and WHtR (OR for X0.59 vs o0.52¼3.10; 95%
CI: 2.03–4.73). No linear trend in risk, however, was observed for
WHR. Compared with the lowest WHR tertile (o0.833), the OR
was 2.10 (95% CI: 1.43–3.09) in the intermediate tertile but 1.33
(95% CI: 0.89–1.97) in the highest tertile (X0.890).
Table 4 shows the relationship between height, WHR and WHtR,
and endometrial cancer risk in strata of BMI at diagnosis.
The tendency of height to be inversely associated with risk was
restricted to overweight and obese women. An increased risk only
in intermediate tertile of WHR was confirmed within all three BMI
strata. Conversely, a nonsignificant direct association with WHtR
was exclusively observed among normal weight women.
The shapes of the best-fitting regression splines for BMI and
WHR are shown in Figure 1. Reference level was set to the median
values of BMI (23) and WHR (0.79) of the reference categories in
the Tables 2 and 3. The association of endometrial cancer risk with
BMI did not show a lower threshold, was monotonic, and risk
increase was steeper after a BMI of B28 (Figure 1A). Conversely,
the relationship between risk and WHR was bell shaped and the
corresponding OR was greatest for WHR between 0.86 and 0.87
(Figure 1B). When the associations of endometrial cancer risk with
BMI and WHR were examined within strata of women with
different characteristics, no statistically significant heterogeneity
was observed by education, smoking habit, and occupational or
recreational physical activity. However, the association with BMI
was somewhat stronger among post-menopausal women (OR for
BMI X30 vs 20 to o25¼4.94; 95% CI: 3.38–7.23) than among
pre- and peri-menopausal women (OR¼2.12; 95% CI: 0.92–4.91),
though this difference was not statistically significant (w
2 for
heterogeneity¼2.04; P¼0.36).
Table 5 shows the association of endometrial cancer risk with
BMI at ages 30 and 50 years within strata of women who had
similar BMI at diagnosis. Some categories of BMI at age 30 and 50
years had to be combined on account of the small numbers
reporting large BMI variations. Among women with BMI o25 at
diagnosis, the OR for BMI X25 vs o25 was 1.24 (95% CI:
0.49–3.13) and 1.59 (95% CI: 0.71–3.52) at ages 30 and 50 years,
respectively. Among women with BMI X30 at diagnosis, the ORs
were 1.23 (95% CI: 0.54–2.82) and 1.60 (95% CI: 0.52–4.96) for a
BMI X30 vs o25 at ages 30 and 50 years, respectively.
No association of perceived body size during adolescence and
endometrial cancer emerged after stratification for BMI at
diagnosis (data not shown).
DISCUSSION
Our case–control study confirms the strong relationship between
weight and BMI at diagnosis and endometrial cancer risk,
especially among post-menopausal women. The effect of BMI did
not show a lower threshold: but the risk curve became steeper
among severely overweight women (BMI 428). After adjustment
or stratification by BMI at diagnosis, history of weight loss and
BMI in young adulthood did not influence endometrial cancer risk.
History of obesity in middle age had, however, a weak
nonsignificant adverse effect among obese women aged 50 years
or older. These findings provide indirect support to the possibility
of weight excess acting as late-stage carcinogens (Parazzini et al
1991; La Vecchia et al 1997). Our BMI results are in broad
agreement with previous work and with a meta-analysis that
showed summary risk estimates of 1.52 (95% CI: 1.35–1.72) in
15 cohort studies and 1.56 (95% CI: 1.45–1.66) in 28 case–control
studies for an increase of 5 BMI units (WCRF/AICR – World
Cancer Research Fund/American Institute for Cancer Research,
2007). The association of BMI with endometrial cancer risk in our
study showed no lower threshold and was nonlinear, in agreement
with the findings of two meta-analyses (Crosbie et al, 2010;
Renehan et al, 2010) that found a highly marked increase in risk
for a BMI above 27.
The relationship between endometrial cancer risk and WHR is
less clear. A meta-analysis of one cohort study and four case–
control studies provided a summary risk estimate of 1.45 (95% CI:
1.00–2.09) for an increase of 0.1 WHR units (WCRF/AICR – World
Cancer Research Fund/American Institute for Cancer Research,
2007). In the Iowa Women’s Health cohort study (Folsom et al,
2000) and in a case–control study (Goodman et al, 1997), included
in the meta-analysis (WCRF/AICR – World Cancer Research Fund/
American Institute for Cancer Research, 2007), the association
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Figure 1 Estimates of odds ratios and 95% confidence intervals of
endometrial cancer by body mass index at diagnosis (A) and waist-to-hip
ratio (B), using cubic regression splines. Italy, 1992–2006 (Odds ratios from
regression equations include terms for age, study centre, year of interview,
education, smoking status, age at menarche, age at menopause, oral
contraceptives use, parity, and hormone replacement therapy use. Curves
are shown for best-fitting cubic spline regression models according to
Akaike Information Criterion. Dashed lines represent 95% confidence
intervals. Ranges represent the distribution of variables among controls
from 10th to 90th percentile). Reference categories were body mass
index¼23 and waist-to-hip ratio¼0.79.
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subsequent cohort studies, the European Prospective Investigation
into Cancer and nutrition (EPIC; Friedenreich et al, 2007), the
Women’s Health Study (Conroy et al, 2009), and the California
Teachers Study (Canchola et al, 2010), two showed a direct
association with WHR (Friedenreich et al, 2007; Canchola et al,
2010), but in both studies the upper quantiles of WHR (40.83 and
X0.80, respectively) were lower than in this study. The reasons for
a bell-shaped relationship between endometrial cancer risk and
WHR are not clear, but may be related to the hormonal correlates of
different types of fat distribution. The effect of body fat distribution
seemed to be weaker and more complex than the effect of weight
excess; risk was clearly associated with both waist and hip
circumference, but the relationship with WHR had a bell shape, at
least among postmenopausal women (80% of study women).
WHtR is another measure of abdominal adiposity that has been
only rarely used in endometrial cancer studies (Canchola et al,
2010). WHtR is considered a measure of visceral fat independent
of height. The overall direct association with WHtR in this study
was stronger than the association with WHR but seemed to be
restricted to normal weight women.
The key interpretation of the relationship between overweight,
obesity, and endometrial cancer is in terms of the ‘unopposed
oestrogen’ hypothesis (Key and Pike, 1988, Parazzini et al, 1991),
that is, of relative excess of oestrogens, following anovulation in
pre-menopause, and androgen conversion to oestrogens in the
adipose tissue in post menopause. In the EPIC study, endometrial
cancer risk in post-menopausal women was directly associated
with the levels of oestrogens and with testosterone, but not with
the levels of androstenedione and dehydroepiandrosterone
(Allen et al, 2008). These findings may explain the weaker
association with WHR than for BMI, in our and other studies
(Austin et al, 1991; Shu et al, 1992; Goodman et al, 1997; Folsom
et al, 2000; Friedenreich et al, 2007; Conroy et al, 2009). WHR is
chiefly a marker of androgenic obesity and hence not strongly
related to oestrogen excess (Seidell et al, 1990, 1989). In one study,
WHR was associated to breast cancer risk in oestrogen receptor
negative, but not in oestrogen receptor positive tumours (Harris
et al, 2011).
In agreement with previous work (WCRF/AICR – World Cancer
Research Fund/American Institute for Cancer Research, 2007;
Crosbie et al, 2010), the association of endometrial cancer risk with
BMI was stronger in post-menopausal women than in pre- and
peri-menopausal women on account of the stronger importance of
oestrogens deriving from androgen conversion after ovarian
activity had ceased. No risk correlates other than menopausal
status modified the association with BMI in our study.
Only a few studies have considered the relationship with lifetime
history of body weight and endometrial cancer risk. A meta-analysis
of BMI in young adulthood showed summary estimates of 1.31 (95%
CI: 1.12–1.54) per 5 BMI unit increase, based on three cohort
studies. The corresponding value, based on six case–control studies,
was 1.10 (95% CI: 0.95–1.27; WCRF/AICR – World Cancer Research
Fund/American Institute for Cancer Research, 2007). Four pro-
spective studies showed a significant direct association between
weight gain during life (measured as weight or BMI variation;
Schouten et al, 2004; Chang et al, 2007; Friedenreich et al, 2007; Park
et al, 2010), whereas another showed no association (Terry et al,
1999). Five case–control studies also reported a direct association of
weight gain with endometrial cancer risk (Levi et al, 1992; Swanson
et al, 1993; Olson et al,1 9 9 5 ;X uet al, 2005; Trentham-Dietz et al,
2006), whereas another study found no relationship (Weiderpass
et al, 2000). A case–control study from China showed a direct
relation with weight at X50 years, but not at younger age (Shu et al,
1992). In our study, we made a special effort to separate the effects
of BMI in young adulthood and middle age and of lifetime weight
changes from the effect of BMI at cancer diagnosis or interview
(controls). We found no evidence of an influence of history of
overweight and obesity after stratification by BMI at diagnosis. Our
findings are, therefore, consistent with excess weight affecting only
late carcinogenesis stages. Only obesity at age 50 years showed an
association of borderline statistical significance among women older
with BMI X30 at diagnosis. This finding is compatible with an effect
of duration of exposure to high levels of circulating oestrogen levels
after menopause.
No association or a weak direct association has been reported
between height and endometrial cancer risk (WCRF/AICR – World
Cancer Research Fund/American Institute for Cancer Research,
Table 5 Distribution of 454 endometrial cancer cases and 908 controls, and corresponding odds ratio (OR) with 95% confidence intervals (CIs)
a, by body
mass index (BMI) at ages 30 and 50 years in strata of BMI at diagnosis,
b Italy, 1992–2006
BMI at age 30 years
c BMI at age 50 years
d
Cases Controls Cases Controls
BMI (kgm
 2) at diagnosis No. (%) No. (%) OR (95% CI) No. (%) No. (%) OR (95% CI)
o25
o25 114 (93.4) 351 (93.4) 1
e 79 (85.9) 270 (89.4) 1
e
X25 8 (6.6) 25 (6.7) 1.24 (0.49–3.13) 13 (14.1) 32 (10.6) 1.59 (0.71–3.52)
X25 to o30
o25 117 (76.5) 237 (75.5) 1
e 55 (42.0) 113 (40.5) 1
e
25 to o30 31 (20.3) 64 (20.4) 0.99 (0.58–1.68) 66 (50.4) 147 (52.7) 1.02 (0.63–1.65)
X30 5 (3.3) 13 (4.1) 0.95 (0.30–3.02) 10 (7.6) 19 (6.8) 1.70 (0.66–4.35)
w
2 for trend (P-value) 0.01 (P¼0.93) 0.52 (P¼0.47)
X30
o25 76 (47.2) 64 (49.6) 1
e 11 (7.5) 10 (8.4) 1
e
25 to o30 61 (37.9) 48 (37.2) 1.12 (0.62–2.00) 51 (34.7) 48 (40.2) 0.89 (0.29–2.76)
X30 24 (14.9) 17 (13.2) 1.23 (0.54–2.82) 85 (57.8) 61 (51.3) 1.60 (0.52–4.96)
w
2 for trend (P-value) 0.29 (P¼0.59)
aORs from conditional logistic regression models, conditioned on age and study centre, adjusted for year of interview, education, smoking status, age at menarche, age at
menopause, oral contraceptives use, parity, and hormone replacement therapy use, when appropriate.
bThe sum does not add up to the total because of some missing values.
cWomen X30 years old only.
dWomen X50 years old only.
eReference category.
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found a weak inverse association, in agreement with some previous
Italian (La Vecchia et al, 1997) and Swiss studies (Levi et al, 1992).
However, in our study the association with height was restricted to
overweight and obese women and was accompanied by a tendency
of control women having BMIX25 to be shorter than leaner
women (data not shown).
Case–control studies may be subject to selection and informa-
tion bias (Breslow and Day, 1980). However, possible sources of
selection bias are limited in our study, as cases and controls were
drawn from the same catchment areas, participation was almost
complete, and women with diseases potentially related to diet and
dietary modifications were excluded from the control group. The
high proportion of missing values for WHR cannot be a source of
bias as it derives from lack of measurement of waist or hip in the
vast majority of women from one centre.
In our study, weights during lifetime and height were self-
reported. It is known that most individuals, and especially those
overweight, tend to underestimate their weight (WCRF/AICR –
World Cancer Research Fund/American Institute for Cancer
Research, 2007). Conversely, height tends to be systematically
overestimated (WCRF/AICR – World Cancer Research Fund/
American Institute for Cancer Research, 2007). As for lifetime
weight history, past body measures were generally well correlated
with corresponding measures (Casey et al 1991), even in older
people (Klipstein-Grobusch et al, 1998). A differential recall between
cases and control is possible, but we do not think that weight and
height were differentially reported by cases and controls. All women
in our study were interviewed in similar hospital settings, and the
general population was unaware of the possible link between
anthropometric measures and endometrial cancer. In addition,
opposite to many other cancers, endometrial cancer is not
frequently preceded by weight loss (De Vita et al,2 0 0 7 ) .
Confounding was dealt with in our study by adjusting for a
broad range of risk correlates, including reproductive and
hormone-related factors. Less than 6% of women reported any
use of lifetime hormone replacement therapy for 2 or more years
(Zucchetto et al, 2009), thus avoiding the need to exclude users
from the assessment of the effects of anthropometric measures.
The implications of this report from a public health viewpoint
are clear. The fraction of endometrial cancer cases attributable to
overweight and obesity in our study population was of 41% (95%
CI: 31–51%; Mezzetti et al, 1996), even higher than the estimated
30% (95% CI: 26–34%) reported for the combination of 30
European countries (Renehan et al, 2010). The predominant
importance of recent weight, compared to lifetime history, justifies
encouraging weight reduction in women at any age.
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